Free Trial

Biodesix (BDSX) Competitors

Biodesix logo
$0.31 -0.01 (-3.20%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BDSX vs. XGN, EUDA, SERA, QIPT, NAKA, KDLY, ATPC, CORBF, OPGN, and PIII

Should you be buying Biodesix stock or one of its competitors? The main competitors of Biodesix include Exagen (XGN), EUDA Health (EUDA), Sera Prognostics (SERA), Quipt Home Medical (QIPT), KindlyMD (NAKA), Kindly MD (KDLY), Agape ATP (ATPC), Global Cord Blood (CORBF), OpGen (OPGN), and P3 Health Partners (PIII). These companies are all part of the "healthcare" industry.

Biodesix vs. Its Competitors

Biodesix (NASDAQ:BDSX) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Biodesix has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Exagen has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.

21.0% of Biodesix shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 30.1% of Biodesix shares are owned by insiders. Comparatively, 12.6% of Exagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Exagen has a net margin of -27.34% compared to Biodesix's net margin of -54.28%. Exagen's return on equity of -133.69% beat Biodesix's return on equity.

Company Net Margins Return on Equity Return on Assets
Biodesix-54.28% -167.28% -39.96%
Exagen -27.34%-133.69%-34.87%

Biodesix currently has a consensus price target of $1.75, indicating a potential upside of 468.18%. Exagen has a consensus price target of $7.50, indicating a potential upside of 7.60%. Given Biodesix's higher probable upside, research analysts clearly believe Biodesix is more favorable than Exagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biodesix
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Exagen
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Biodesix's average media sentiment score of 0.00 equaled Exagen'saverage media sentiment score.

Company Overall Sentiment
Biodesix Neutral
Exagen Neutral

Exagen has lower revenue, but higher earnings than Biodesix. Exagen is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biodesix$74.46M0.61-$42.93M-$0.29-1.06
Exagen$55.64M2.67-$15.11M-$0.84-8.30

Summary

Exagen beats Biodesix on 9 of the 14 factors compared between the two stocks.

Get Biodesix News Delivered to You Automatically

Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BDSX vs. The Competition

MetricBiodesixMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$45.00M$7.31B$5.57B$9.02B
Dividend YieldN/A2.80%5.25%4.03%
P/E Ratio-1.0627.5827.2120.15
Price / Sales0.6134.91416.26185.35
Price / CashN/A23.6737.0657.97
Price / Book2.206.888.085.60
Net Income-$42.93M$230.16M$3.16B$248.50M
7 Day Performance11.59%2.13%3.74%5.11%
1 Month Performance-6.67%2.56%3.88%7.58%
1 Year Performance-80.99%45.16%34.26%21.53%

Biodesix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BDSX
Biodesix
3.4039 of 5 stars
$0.31
-2.6%
$1.75
+468.2%
-80.5%$45.00M$74.46M-1.06220
XGN
Exagen
2.9713 of 5 stars
$6.96
-1.3%
$7.50
+7.8%
+261.4%$150.16M$55.64M0.00220
EUDA
EUDA Health
N/A$3.33
-1.5%
N/A-15.9%$125.59M$4.01M0.002Gap Up
SERA
Sera Prognostics
0.6447 of 5 stars
$2.42
-2.8%
N/A-49.7%$93.81M$80K0.00120Positive News
Gap Down
QIPT
Quipt Home Medical
2.9613 of 5 stars
$1.73
-2.8%
$2.85
+64.7%
-36.3%$77.33M$245.91M0.001,200Analyst Revision
NAKA
KindlyMD
N/A$12.04
-5.6%
N/AN/A$76.88M$2.72M-15.64N/ANews Coverage
Positive News
KDLY
Kindly MD
N/A$12.75
-2.8%
N/A+426.9%$76.78M$2.47M-16.56N/A
ATPC
Agape ATP
0.2459 of 5 stars
$1.40
+2.6%
N/A-64.4%$68.01M$1.32M-2.3240News Coverage
CORBF
Global Cord Blood
N/A$0.55
-62.1%
N/A-54.1%$66.85M$196.12M0.001,200Gap Up
OPGN
OpGen
N/A$5.02
+6.1%
N/A+59.2%$50.54M$2.67M0.00100Gap Down
PIII
P3 Health Partners
2.9184 of 5 stars
$6.40
+0.3%
$16.25
+153.9%
-74.4%$45.86M$1.50B0.00500Gap Down

Related Companies and Tools


This page (NASDAQ:BDSX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners